MDR TB is a significant public health concern because it is more complex and expensive to treat than drug-susceptible TB. Treatment requires longer courses of second-line drugs, which are less effective, more toxic, and much costlier. Moreover, MDR TB has a lower treatment success rate, leading to higher mortality rates.
